Probi

185SEK -2,12 %
Vær den første som følger denne virksomhed

Probi is a biotechnology company. The company is particularly focused on the research and development of probiotics, a bacterium that is found in the human intestinal system. The research areas within the company include the gastrointestinal, immune system, metabolic syndrome, and stress and recovery. The company's customers include larger corporate customers active in the food industry. The company was founded in 1991 and is headquartered in Lund.

Omsætning
618,29 mio.
EBIT %
8,18 %
P/E
51,82
Udbytteafkast, %
0,7 %
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
PROB
Daglig lav / høj pris
179,5 / 189 SEK
Markedsværdi
2,11 mia. SEK
Aktieomsætning
420,72 t SEK
Volumen
2,3 t
Probi's Annual General Meeting 2023

Selskabsmeddelelse04.05.2023
Probi: Q3 2022: Weaker growth in US

Selskabsmeddelelse21.10.2022
Probi: Weaker growth in US

Selskabsmeddelelse10.10.2022